NCT02311413

A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

The Effect of Peptide Immunotherapy on Frequency, Memory Phenotype, Chemokine Receptor Expression and Markers of Regulatory T Cell Function Among Allergen-Specific T Cells

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · NIH
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).

Detailed description

Cat-PAD is an experimental cat allergy vaccine and has been studied to determine if it can reduce symptom scores of participants exposed to cat allergen. To study how the vaccine causes changes in the immune system, the researchers plan to evaluate changes in the blood (genes and proteins) and urine in response to the Cat-PAD vaccine.

Conditions

• Cat Allergy
• Cat Hypersensitivity

Interventions

Type	Name	Description
DRUG	Cat-PAD	The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
DRUG	Placebo	The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.

Timeline

• Start date: 2015-03-09
• Primary completion: 2018-07-18
• Completion: 2018-07-18
• First posted: 2014-12-08
• Last updated: 2018-11-02

Locations

1 site across 1 country: Canada